Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model


Abbott Laboratories



) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 1.3%. By the end of trading, Abbott Laboratories rose $1.14 (1.8%) to $64.47 on light volume. Throughout the day, 2.8 million shares of Abbott Laboratories exchanged hands as compared to its average daily volume of 7.3 million shares. The stock ranged in a price between $63.44-$64.49 after having opened the day at $63.48 as compared to the previous trading day's close of $63.33. Other companies within the Drugs industry that increased today were:

MAP Pharmaceuticals



), up 20.3%,

Star Scientific



), up 13.6%,

Rosetta Genomics



), up 12.9%, and

Coronado Biosciences



), up 12.6%.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products worldwide. Abbott Laboratories has a market cap of $100.1 billion and is part of the health care sector. The company has a P/E ratio of 15.5, below the S&P 500 P/E ratio of 17.7. Shares are up 12.6% year to date as of the close of trading on Wednesday. Currently there are six analysts that rate Abbott Laboratories a buy, no analysts rate it a sell, and 12 rate it a hold.

TheStreet Ratings rates Abbott Laboratories as a


. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, largely solid financial position with reasonable debt levels by most measures and reasonable valuation levels. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.

On the negative front,

Dynavax Technologies Corporation



), down 5.5%,




), down 4.8%,

Biocryst Pharmaceuticals



), down 4.7%, and

Biostar Pharmaceuticals



), down 4.7%, were all laggards within the drugs industry with




) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF



) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech




FREE for a limited time only: Get TheStreet Ratings #1 Stock Report NOW!